2024
Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial
Kandzari D, Weber M, Pathak A, Zidar J, Saxena M, David S, Schmieder R, Janas A, Langer C, Persu A, Mendelsohn F, Ameloot K, Foster M, Fischell T, Parise H, Mahfoud F. Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial. Circulation 2024, 149: 1875-1884. PMID: 38587557, DOI: 10.1161/circulationaha.124.069291.Peer-Reviewed Original ResearchSystolic blood pressureOffice systolic blood pressureRenal denervationOffice diastolic BPAmbulatory systolic BPBlood pressureSham controlsPrimary endpointBetween-group differencesNo significant differenceAntihypertensive medicationsDiastolic BPSystolic BPPresence of antihypertensive medicationBaseline-adjusted changeRenal artery dissectionMonths post-procedureSignificant differenceRenal denervation groupAmbulatory systolic blood pressureNo significant between-group differencesStatistically significant reductionSignificant between-group differencesSecondary endpointsOffice BP
2023
Alcohol-mediated renal denervation in patients with hypertension in the absence of antihypertensive medications.
Pathak A, Rudolph U, Saxena M, Zeller T, Müller-Ehmsen J, Lipsic E, Schmieder R, Sievert H, Halbach M, Sharif F, Parise H, Fischell T, Weber M, Kandzari D, Mahfoud F. Alcohol-mediated renal denervation in patients with hypertension in the absence of antihypertensive medications. EuroIntervention 2023, 19: 602-611. PMID: 37427416, PMCID: PMC10493775, DOI: 10.4244/eij-d-23-00088.Peer-Reviewed Original ResearchConceptsSystolic blood pressureRenal denervationBlood pressureAntihypertensive medicationsRDN groupMedication burdenMean office blood pressureOffice systolic blood pressureSystolic BP 140Office blood pressurePrimary efficacy endpointMajor adverse eventsSystolic BP changeDiastolic blood pressureLower blood pressureRadiofrequency renal denervationLower medication burdenSignificant BP differencesMedication escalationEfficacy endpointSafety endpointAdverse eventsSham groupBP changesMedication washout
2022
Impact of drug adherence on blood pressure response to alcohol-mediated renal denervation
Persu A, Maes F, Toennes S, Ritscher S, Georges C, Wallemacq P, Haratani N, Parise H, Fischell T, Lauder L, Mahfoud F. Impact of drug adherence on blood pressure response to alcohol-mediated renal denervation. Blood Pressure 2022, 31: 109-117. PMID: 35575248, DOI: 10.1080/08037051.2022.2074367.Peer-Reviewed Original ResearchConceptsRenal denervationDrug adherenceBlood pressure changesNon-adherent patientsPoor drug adherenceTreatment-resistant hypertensionSham-controlled trialBlood pressure responseSystolic blood pressureUncontrolled hypertensionAntihypertensive medicationsResistant hypertensionSuch patientsBlood pressureAntihypertensive drugsDenervationMean 24Partial adherencePatientsFull adherenceUrinary detectionHypertensionPressure changesLiquid chromatography-tandem mass spectrometryAdherence
2018
CHEMICAL RENAL DENERVATION WITH ALCOHOL – LONG TERM RESULTS FROM THE PEREGRINE POST-MARKET STUDY
Persu A, Renkin J, Hochul M, Wojakowski W, Böhm M, Mahfoud F, Schmieder R, van der Giet M, de Bucourt M, Zirlik A, Neuzil P, Haratani N, Parise H, Fischell T, Bertog S, Sievert K, Sievert H. CHEMICAL RENAL DENERVATION WITH ALCOHOL – LONG TERM RESULTS FROM THE PEREGRINE POST-MARKET STUDY. Journal Of Hypertension 2018, 36: e123. DOI: 10.1097/01.hjh.0000539319.18701.45.Peer-Reviewed Original ResearchSystolic office blood pressureChemical renal denervationResistant hypertensionPost-market studyRenal denervationVascular access site complicationsWhite-coat resistant hypertensionMajor efficacy endpointsMulticenter European trialSignificant BP reductionOffice blood pressureRenal artery dissectionTransient ischemic attackAccess site complicationsAnti-hypertensive medicationsMean procedure timeMajor safety endpointsML of alcoholAnatomical eligibilityAntihypertensive medicationsBP reductionEligible patientsIschemic attackOpen labelRenal events